Please login to the form below

Not currently logged in
Email:
Password:

Lynparza

This page shows the latest Lynparza news and features for those working in and with pharma, biotech and healthcare.

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

It’s a familiar approach for Merck’s chief executive Ken Frazier, coming after a similar $8.5bn deal with AstraZeneca involving PARP inhibitor Lynparza (olaparib), which also included a product ... as with the Lynparza deal will start to generate

Latest news

  • CHMP backs AZ’s Lynparza for ovarian cancer maintenance CHMP backs AZ’s Lynparza for ovarian cancer maintenance

    CHMP backs AZ’ s Lynparza for ovarian cancer maintenance. Studies show that the drug reduced risk of disease progression. ... Lynparza can be used in these patients regardless of the patient’s BRCA status, said AZ and Merck.

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    The CHMP also gave positive opinions to: a new maintenance indication for AstraZeneca and Merck &Co’s PARP inhibitor Lynparza (olaparib) in ovarian cancer; the use of Swedish orphan Biovitrum’s

  • AZ expects return to growth this year after 2017 decline AZ expects return to growth this year after 2017 decline

    AZ brought five new medicines to market in 2017 - including new cancer medicines Imfinzi (durvalumab) and Calquence (acalabrutinib) as well as Fasenra (benralizumab) for asthma - and added new indications for Lynparza ... PARP inhibitor Lynparza for

  • AZ and Merck & Co get FDA breast cancer nod for Lynparza AZ and Merck & Co get FDA breast cancer nod for Lynparza

    The US regulator has given the go-ahead for Lynparza (olaparib) for patients with HER2-negative tumours with BRCA mutations who have been previously treated with chemotherapy. ... In the OLYMPIAD trial, Lynparza achieved a statistically-significant and

  • AZ CEO says company’s renaissance is on track AZ CEO says company’s renaissance is on track

    Gains for lung cancer therapy Tagrisso (osimertinib) - up 86% to $248m in the quarter - plus a $997m payment from MSD related to AZ’s licensing deal for ovarian cancer medicine Lynparza ... AZ’s deal with MSD for Lynparza was signed in July and

More from news
Approximately 18 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    in the EGFR-TK gene and Lynparza, which is approved to treat ovarian cancer patients with the BRCA mutation. “ ... 2015. “ Lynparza is for a very specific population of platinum sensitive relapse patients,” explains Anson. “

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics